Loading patent…
AssigneeDaiichi Sankyo Company, Limited
InventorsShinnosuke YAMADA, Naoki KIYOSAWA
Estimating the term…
The present invention provides a gene set for predicting the sensitivity of a cancer to a treatment with a PD-1 immune checkpoint inhibitor. More specifically, the present invention provides one or more genes selected from the group consisting of ADAM8, VCL, LEF1-AS1, TSPAN32, CTBP2, RXRA, PTGDS, ITGB1, KLRD1, RAB11FIP5, SLC4A8, NIN, GCNT2, ASB2, HNRPLL, AMPD3, SIRPG, PTPN13, MYB, ASAP1, MBOAT1, COTL1, ICOS, ST8SIA1, PASK, SGPP2, PDCD1, TBC1D4, EMP3, FAM65B, GBP1, FAM211B, PRR5, C17orf67, FAM101B and TBL1X, and a method for predicting the sensitivity of a cancer to a treatment with a PD-1 immune checkpoint inhibitor by using the genes.
A method for predicting sensitivity of a cancer or a tumor of a subject to a treatment with a PD-1 immune checkpoint inhibitor, comprising measuring an expression level(s) of one or more genes selected from the group consisting of the following genes:
A gene signature comprising one or more genes selected from the group consisting of ADAM8, VCL, LEF1-AS1, TSPAN32, CTBP2, RXRA, PTGDS, ITGB1, KLRD1, RAB11FIP5, SLC4A8, NIN, GCNT2, ASB2, HNRPLL, AMPD3, SIRPG, PTPN13, MYB, ASAP1, MBOAT1, COTL1, ICOS, ST8SIA1, PASK, SGPP2, PDCD1, TBC1D4, EMP3, FAM65B, GBP1, FAM211B, PRR5, C17orf67, FAM101B and TBL1X, for use in predicting whether or not a cancer or a tumor is sensitive to a treatment with a PD-1 immune checkpoint inhibitor.
A combination of nucleic acid probes or primer sets for a plurality of genes selected from the group consisting of ADAM8, VCL, LEF1-AS1, TSPAN32, CTBP2, RXRA, PTGDS, ITGB1, KLRD1, RAB11FIP5, SLC4A8, NIN, GCNT2, ASB2, HNRPLL, AMPD3, SIRPG, PTPN13, MYB, ASAP1, MBOAT1, COTL1, ICOS, ST8SIA1, PASK, SGPP2, PDCD1, TBC1D4, EMP3, FAM65B, GBP1, FAM211B, PRR5, C17orf67, FAM101B and TBL1X.
A kit for use in determining sensitivity to a treatment with a PD-1 immune checkpoint inhibitor, comprising
Dependencies are inferred from the claim text.